NCT06537999

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Dianthus Therapeutics · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with multifocal motor neuropathy (MMN).

Conditions

• Multifocal Motor Neuropathy

Interventions

Type	Name	Description
DRUG	DNTH103	* Day 1: IV loading dose * Week 1 to Week 15: DNTH103 administered SC every 2 weeks
DRUG	Placebo	* Day 1: IV infusion of placebo * Week 1 to Week 15: placebo administered SC every 2 weeks

Timeline

• Start date: 2024-09-17
• Primary completion: 2026-06-30
• Completion: 2028-03-31
• First posted: 2024-08-05
• Last updated: 2025-10-06

Locations

26 sites across 10 countries: United States, Denmark, France, Italy, Netherlands, North Macedonia, Poland, Serbia, Spain, United Kingdom

Regulatory

• FDA-regulated drug study